NPB-01

Phase 3Small molecule

NPB-01 is one of 129 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Bullous PemphigoidActive, not recruiting

Autoimmune EncephalitisActive, not recruiting

Neuromyelitis OpticaActive, not recruiting

NeuropathyActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Active, not recruiting

Bullous PemphigoidPhase 2

Active, not recruiting

Autoimmune EncephalitisPhase 3

Active, not recruiting

Neuromyelitis OpticaPhase 2

Active, not recruiting

NeuropathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

114 competitors in Neuropathy

#DrugCompanyPhaseTrials

Asceniv

CSL Behring

Phase 3

1 2

Avandia

Alnylam Pharmaceuticals

Phase 3

1 3

Savella

AbbVie

Phase 3

1 4

Vimpat

UCB

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

3 6

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 3

1 7

Claritin

PPerrigo Company

Phase 3

1 8

Glutamine

Sanofi

Phase 3

2 9

Curcumin

Merck & Co.

Phase 3

1 10

Rituxan

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bullous Pemphigoid2 trials

Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.

Completed·NNihon Pharmaceutical Co., Ltd·Phase 2·NCT00809822·20 enrolled

Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids

Completed·NNihon Pharmaceutical Co., Ltd·Phase 3·NCT01408550·56 enrolled

Clinical Trial1 trial

Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome

Completed·NNihon Pharmaceutical Co., Ltd·Phase 3·NCT02221271·22 enrolled

Neuropathy1 trial

Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.

Completed·NNihon Pharmaceutical Co., Ltd·Phase 3·NCT01827072·13 enrolled

Neuromyelitis Optica1 trial

Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

Completed·NNihon Pharmaceutical Co., Ltd·Phase 2·NCT01845584·7 enrolled

Autoimmune Encephalitis1 trial

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

Unknown status·NNihon Pharmaceutical Co., Ltd·Phase 3·NCT05177939·40 enrolled

1 more indication

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Completed·NNihon Pharmaceutical Co., Ltd·Phase 3·NCT01824251·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for NPB-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NPB-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NPB-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nihon Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNihon Pharmaceutical Co., Ltd

NPB-01

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bullous Pemphigoid2 trials

Clinical Trial1 trial

Neuropathy1 trial

Neuromyelitis Optica1 trial

Autoimmune Encephalitis1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

References

Drug Info

Quick Facts

Related News